$PTCT
PTC THERAPEUTICS, INC. Stock $ptct

$ptct Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000107008121000017 Filed on May 04, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$117.9M	$68.26M
YoY Change	72.79%	27.39%
Cost Of Revenue	$9.100M	$4.100M
YoY Change	121.95%	72.56%
Gross Profit	$108.8M	$64.20M
YoY Change	69.47%	25.37%
Gross Profit Margin	92.25%	94.05%
Selling, General & Admin	$61.10M	$58.21M
YoY Change	4.96%	43.57%
% of Gross Profit	56.15%	90.67%
Research & Development	$134.5M	$90.11M
YoY Change	49.28%	71.42%
% of Gross Profit	123.63%	140.35%
Depreciation & Amortization	$13.59M	$9.235M
YoY Change	47.13%	30.83%
% of Gross Profit	12.49%	14.38%
Operating Expenses	$216.1M	$161.3M
YoY Change	34.01%	31.39%
Operating Profit	-$98.15M	-$92.99M
YoY Change	5.55%	34.5%
Interest Expense	-$19.16M	-$5.642M
YoY Change	239.58%	146.59%
% of Operating Profit
Other Income/Expense, Net	-$10.88M	-$13.83M
YoY Change	-21.31%	12589.91%
Pretax Income	-$128.2M	-$112.5M
YoY Change	13.98%	57.21%
Income Tax	$451.0K	$222.0K
% Of Pretax Income
Net Earnings	-$128.6M	-$112.7M
YoY Change	14.16%	56.26%
Net Earnings / Revenue	-109.07%	-165.09%
Basic Earnings Per Share	-$1.83
Diluted Earnings Per Share	-$1.83	-$1.806M
COMMON SHARES
Basic Shares Outstanding	70.19M	62.63M shares
Diluted Shares Outstanding	70.19M

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$988.4M	$595.9M
YoY Change	65.87%	46.34%
Cash & Equivalents	$146.6M	$123.3M
Short-Term Investments	$841.8M	$472.6M
Other Short-Term Assets	$23.60M	$24.30M
YoY Change	-2.88%	161.29%
Inventory	$16.23M	$19.13M
Prepaid Expenses
Receivables	$94.10M	$52.60M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.122B	$691.9M
YoY Change	62.21%	44.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$37.12M	$26.17M
YoY Change	41.86%	79.98%
Goodwill	$82.30M	$82.30M
YoY Change	0.0%	-0.05%
Intangibles	$712.6M	$705.3M
YoY Change	1.03%	1.49%
Long-Term Investments
YoY Change
Other Assets	$75.20M	$22.20M
YoY Change	238.74%	865.22%
Total Long-Term Assets	$989.6M	$853.7M
YoY Change	15.92%	6.07%
TOTAL ASSETS
Total Short-Term Assets	$1.122B	$691.9M
Total Long-Term Assets	$989.6M	$853.7M
Total Assets	$2.112B	$1.546B
YoY Change	36.64%	20.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.11M	$16.07M
YoY Change	18.91%	64.26%
Accrued Expenses	$68.50M	$52.20M
YoY Change	31.23%	117.5%
Deferred Revenue	$1.887M	$8.638M
YoY Change	-78.15%	57.14%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$34.80M	$20.00M
YoY Change	74.0%	20.0%
Total Short-Term Liabilities	$250.9M	$217.7M
YoY Change	15.29%	52.17%
LONG-TERM LIABILITIES
Long-Term Debt	$430.0M	$294.6M
YoY Change	45.99%	112.74%
Other Long-Term Liabilities	$1.392M	$14.79M
YoY Change	-90.59%	68.6%
Total Long-Term Liabilities	$431.4M	$309.4M
YoY Change	39.46%	110.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$250.9M	$217.7M
Total Long-Term Liabilities	$431.4M	$309.4M
Total Liabilities	$1.819B	$1.017B
YoY Change	78.92%	31.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.703B	-$1.303B
YoY Change	30.64%	28.92%
Common Stock	$70.00K	$62.00K
YoY Change	12.9%	6.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$292.6M	$528.7M
YoY Change
Total Liabilities & Shareholders Equity	$2.112B	$1.546B
YoY Change	36.64%	20.38%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$128.6M	-$112.7M
YoY Change	14.16%	56.26%
Depreciation, Depletion And Amortization	$13.59M	$9.235M
YoY Change	47.13%	30.83%
Cash From Operating Activities	-$100.2M	-$81.55M
YoY Change	22.81%	92.3%
INVESTING ACTIVITIES
Capital Expenditures	$5.669M	$6.023M
YoY Change	-5.88%	110.23%
Acquisitions
YoY Change
Other Investing Activities	$35.82M	-$95.25M
YoY Change	-137.61%	-35.48%
Cash From Investing Activities	$30.15M	-$101.3M
YoY Change	-129.77%	-32.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$13.50M
YoY Change		-93.98%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	9.531M	18.49M
YoY Change	-48.45%	-91.81%
NET CHANGE
Cash From Operating Activities	-100.2M	-81.55M
Cash From Investing Activities	30.15M	-101.3M
Cash From Financing Activities	9.531M	18.49M
Net Change In Cash	-62.18M	-164.7M
YoY Change	-62.26%	-620.57%
FREE CASH FLOW
Cash From Operating Activities	-$100.2M	-$81.55M
Capital Expenditures	$5.669M	$6.023M
Free Cash Flow	-$105.8M	-$87.58M
YoY Change	20.84%	93.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001070081
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70405905
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69718096
CY2021Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-35969
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	PTC Therapeutics, Inc.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3416587
CY2021Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1694000
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Corporate Court
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	South Plainfield,
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07080
CY2021Q1	dei	City Area Code CityAreaCode	908
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	222-7000
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2021Q1	dei	Trading Symbol TradingSymbol	PTCT
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70455908
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	146632000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	208812000
CY2021Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	841774000
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	894838000
CY2021Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	94124000
CY2020Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	69929000
CY2021Q1	us-gaap	Inventory Net InventoryNet	16234000
CY2020Q4	us-gaap	Inventory Net InventoryNet	18697000
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23601000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	39469000
CY2021Q1	us-gaap	Assets Current AssetsCurrent	1122365000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1231745000
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37123000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33831000
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	712574000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	715328000
CY2021Q1	us-gaap	Goodwill Goodwill	82341000
CY2020Q4	us-gaap	Goodwill Goodwill	82341000
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	82382000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	84410000
CY2021Q1	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	75156000
CY2020Q4	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	60623000
CY2021Q1	us-gaap	Assets Assets	2111941000
CY2020Q4	us-gaap	Assets Assets	2208278000
CY2021Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	205636000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	242168000
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1887000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4151000
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7333000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7465000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1276000
CY2021Q1	ptct	Liability Sale Of Future Royalties Current LiabilitySaleOfFutureRoyaltiesCurrent	33149000
CY2020Q4	ptct	Liability Sale Of Future Royalties Current LiabilitySaleOfFutureRoyaltiesCurrent	21023000
CY2021Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1250000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1250000
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	250949000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	277333000
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	430038000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	309145000
CY2021Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	240500000
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	240400000
CY2021Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	136735000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	136735000
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	77863000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	79499000
CY2021Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20053000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	23053000
CY2021Q1	ptct	Liability Sale Of Future Royalties Noncurrent LiabilitySaleOfFutureRoyaltiesNoncurrent	661835000
CY2020Q4	ptct	Liability Sale Of Future Royalties Noncurrent LiabilitySaleOfFutureRoyaltiesNoncurrent	658739000
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1392000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1392000
CY2021Q1	us-gaap	Liabilities Liabilities	1819365000
CY2020Q4	us-gaap	Liabilities Liabilities	1726296000
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70405905
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69718096
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	70000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	70000
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2033972000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2171746000
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-38743000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-60957000
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1702723000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1628877000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	292576000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	481982000
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2111941000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2208278000
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	117942000
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	68259000
CY2021Q1	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	9104000
CY2020Q1	ptct	Costof Goodsand Service Excluding Amortization Of Intangible Assets CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets	4085000
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11278000
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7949000
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	134513000
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	90107000
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61095000
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	58209000
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	-100000
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	-900000
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	216090000
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	161250000
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-98148000
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-92991000
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-19159000
CY2020Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-5642000
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10884000
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13832000
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-128191000
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-112465000
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	451000
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	222000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-128642000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-112687000
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	70188602
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62389158
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.83
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.81
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-128642000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-112687000
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	0
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	0
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-1294000
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-63000
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	23508000
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	8662000
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-106428000
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-104088000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	481982000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11755000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25707000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-128642000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	22214000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	292576000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	594330000
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13503000
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9987000
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15220000
CY2020Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	218000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-112687000
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	8599000
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	528734000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-128642000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-112687000
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13587000
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9235000
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1819000
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1330000
CY2021Q1	ptct	Noncash Royalty Revenue Sale Of Future Royalties NoncashRoyaltyRevenueSaleOfFutureRoyalties	2858000
CY2021Q1	ptct	Noncash Interest Expense Liability Related To Sale Of Future Royalties NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	18080000
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	100000
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	900000
CY2021Q1	ptct	Clearpoint Equity Investment Fvni Unrealized Gain Loss ClearpointEquityInvestmentFvniUnrealizedGainLoss	6764000
CY2020Q1	ptct	Clearpoint Equity Investment Fvni Unrealized Gain Loss ClearpointEquityInvestmentFvniUnrealizedGainLoss	-1574000
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	7858000
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-2799000
CY2021Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-302000
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1359000
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	333000
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	452000
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	256000
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	25707000
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	15220000
CY2020Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	5459000
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-24691000
CY2020Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-8675000
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1963000
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-102000
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-15605000
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6675000
CY2021Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	25010000
CY2020Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-2346000
CY2021Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-136000
CY2020Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	192000
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-28756000
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4000000
CY2021Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1916000
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-4363000
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2154000
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1200000
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-100157000
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-81554000
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5669000
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6023000
CY2020Q1	ptct	Payments To Acquire Convertible Debt Investment PaymentsToAcquireConvertibleDebtInvestment	10000000
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	141985000
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	298814000
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	200000000
CY2021Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	392093000
CY2020Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	224997000
CY2021Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	14192000
CY2020Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	11434000
CY2021Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	100000
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	30147000
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-101274000
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11755000
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9987000
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13503000
CY2020Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	5000000
CY2021Q1	ptct	Payment Of Finance Lease Principal PaymentOfFinanceLeasePrincipal	2224000
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9531000
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18490000
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1701000
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-403000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-62180000
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-164741000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	216312000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	295528000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154132000
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130787000
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	5182000
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	4878000
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	687000
CY2020Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	507000
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-1294000
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-63000
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	13000
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	22642000
CY2021Q1	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	8870000
CY2020Q1	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	2775000
CY2021Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. The Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PTC Therapeutics, Inc. (the “Company” or “PTC”) is a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company’s ability to globally commercialize products is the foundation that drives its continued investment in a robust diversified pipeline of transformative medicines and its mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company’s strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has two products, Translarna™ (ataluren) and Emflaza™ (deflazacort), for the treatment of Duchenne muscular dystrophy (“DMD”), a rare, life threatening disorder. Translarna has marketing authorization in the European Economic Area (the “EEA”) for the treatment of nonsense mutation Duchenne muscular dystrophy (“nmDMD”) in ambulatory patients aged 2 years and older and in Brazil for the treatment of nmDMD in ambulatory patients aged 5 years and older, subject to annual renewal and other conditions. In July 2020, the European Commission approved the removal of the statement “efficacy has not been demonstrated in non-ambulatory patients” from the indication statement for Translarna. Emflaza is approved in the United States for the treatment of DMD in patients two years and older.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company holds the rights for the commercialization of Tegsedi™ (inotersen) and Waylivra™ (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to the Collaboration and License Agreement (the “Akcea Collaboration and License Agreement”), dated August 1, 2018, by and between the Company and Akcea Therapeutics, Inc. (“Akcea”). Tegsedi has received marketing authorization in the United States, the European Union (the “EU”) and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (“hATTR amyloidosis”). While the Company is in the process of initiating its<span style="background-color:#ffffff;"> commercial launch for Tegsedi for the treatment of hATTR amyloidosis in Latin America, it continues to make Tegsedi available in certain countries within Latin America and the Caribbean through early access programs. </span>Waylivra has received marketing authorization in the EU for the treatment of familial chylomicronemia syndrome (“FCS”). The Company filed for marketing authorization for Waylivra for the treatment of FCS with ANVISA, the Brazilian health regulatory authority, in June 2020 and, subject to potential delays in the review process related to the COVID-19 pandemic, expects a regulatory decision on approval from ANVISA in the third quarter of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also has a spinal muscular atrophy (“SMA”) collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. (referred to collectively as “Roche”) and the Spinal Muscular Atrophy Foundation (“SMA Foundation”). The SMA program has one approved product, Evrysdi™ (risdiplam), which was approved by the United States Food and Drug Administration (“FDA”) in August 2020 for the treatment of SMA in adults and children two months and older and by the European Commission in March 2021 for the treatment of 5q SMA in patients two months and older with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi also received marketing authorization for the treatment of SMA in Brazil in October 2020. Additionally, in October 2020, Chugai Pharmaceutical Co., Ltd. (“Chugai”), a subsidiary of Roche, filed a New Drug Application (“NDA”) in Japan for Evrysdi for the treatment of SMA and a regulatory decision on approval is expected in 2021. In addition to the Company’s SMA program, the Company’s splicing platform also includes PTC518, which is being developed for the treatment of Huntington’s disease (“HD”). The Company announced preliminary results from its ongoing Phase 1 study of PTC518 in healthy volunteers in April 2021 demonstrating dose-dependent lowering of huntingtin messenger ribonucleic acid levels and that PTC518 was well tolerated with no safety-related findings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (“CNS”) including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (“AADC”) deficiency (“AADC deficiency”), a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. In January 2020, the Company submitted an MAA to the European Medicines Agency </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(“EMA”) for PTC-AADC for the treatment of AADC deficiency in the EEA, and the Company expects an opinion from the <span style="background-color:#ffffff;">Committee for Medicinal Products for Human Use (“CHMP”)</span> in the third quarter of 2021. The Company is also preparing a biologics license application (“BLA”) for PTC-AADC for the treatment of AADC deficiency in the United States. The Company anticipates the BLA submission to the FDA to be delayed by at least one quarter. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s Bio-e platform consists of small molecule compounds that target oxidoreductase enzymes that regulate oxidative stress and inflammatory pathways central to the pathology of a number of CNS diseases. The two most advanced molecules in the Company’s Bio-e platform are vatiquinone and PTC857. The Company initiated a registration-directed Phase 2/3 placebo-controlled trial of vatiquinone in children with mitochondrial disease and associated refractory epilepsy in the third quarter of 2020 and anticipates data from this trial to be available in the third quarter of 2022. The Company also initiated a registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia in the fourth quarter of 2020 and anticipates data from this trial to be available in 2023. In the second quarter of 2020, the Company initiated a Phase 1 trial in healthy volunteers to evaluate the safety and pharmacology of PTC857. This Phase 1 trial was recently completed and the Company expects data to be available in the second quarter of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 29, 2020, the Company completed its acquisition of Censa Pharmaceuticals, Inc. (“Censa”) pursuant to an Agreement and Plan of Merger, dated as of May 5, 2020 (the "Censa Merger Agreement"), by and among the Company, Hydro Merger Sub, Inc., the Company’s wholly owned, indirect subsidiary, and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC (the "Censa Merger"). The transaction was accounted for as an asset acquisition. In connection with the Censa Merger, the Company acquired PTC923, an oral formulation of synthetic sepiapterin, a precursor to intracellular tetrahydrobiopterin, which is a critical enzymatic cofactor involved in metabolism and synthesis of numerous metabolic products. The Company expects to initiate a registration-directed Phase 3 trial for PTC923 for phenylketonuria (“PKU”) in mid-2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company initiated a Phase 2/3 clinical trial evaluating the efficacy and safety of PTC299, a dihydroorotate dehydrogenase inhibitor that the Company has also been developing in oncological indications, in patients hospitalized with COVID-19. The Company expects data from this trial to be available in the second half of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. This marketing authorization is further subject to the specific obligation to conduct and submit the results of a multi-center, randomized, double-blind, 18 month, placebo-controlled trial, followed by an 18 month open-label extension, according to an agreed protocol, in order to confirm the efficacy and safety of Translarna. The final report on the trial and open-label extension is to be submitted by the Company to the EMA by the end of the third quarter of 2022. The Company refers to the trial and open-label extension together as Study 041.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The marketing authorization in the EEA was last renewed in June 2020 and is effective, unless extended, through August 5, 2021. <span style="background-color:#ffffff;">In February 2021, the Company submitted a marketing authorization renewal request to the EMA. </span>The renewal was based on the Company’s commitment to conduct Study 041 and the totality of the clinical data available from its trials and studies of Translarna for the treatment of nmDMD, including the safety and efficacy results of the Phase 2b and Phase 3 clinical trials. The primary efficacy endpoint was not achieved in either trial within the pre-specified level of statistical significance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Translarna is an investigational new drug in the United States. During the first quarter of 2017, the Company filed a New Drug Application (“NDA”) over protest with the FDA, for which the FDA granted a standard review. In October 2017, the Office of Drug Evaluation I of the FDA issued a complete response letter for the NDA, stating that it was unable to approve the application in its current form. In response, the Company filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied the Company’s appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients’ muscles. The Company followed the FDA’s recommendation and collected, using newer technologies via procedures and methods that the Company designed, such dystrophin data in a new study, Study 045, and announced the results of Study 045 in February 2021. Although Study 045 did not meet its pre-specified primary endpoint, the Company plans to discuss the Study 045 dystrophin results and the totality of existing clinical and real-world data with the FDA to determine if there is a potential path to approval based on these results and data. There is substantial risk that the FDA will determine that the results from the Company’s clinical trials and existing real-world data are not sufficient to support a marketing approval for Translarna for the treatment of nmDMD in the United States. In that case, as the Company expects to have data for Study 041 in the third quarter of 2022, and subject to a positive outcome in that study, the Company would plan to re-submit the NDA at that time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of March 31, 2021, the Company had an accumulated deficit of approximately $1,702.7 million. The Company has financed its operations to date primarily through the private offerings in September 2019 of 1.50% convertible senior notes due 2026 and in August 2015 of 3.00% convertible senior notes due 2022 (collectively, the “Convertible Notes”) (see Note 9), public offerings of common stock in February 2014, October 2014, April 2018, January 2019, and September 2019, "at the market offerings" of its common stock, its initial public offering of common stock in June 2013, proceeds from a Royalty Purchase Agreement dated as of July 17, 2020, by and among the Company, RPI 2019 Intermediate Finance Trust (“RPI”), and, solely for the limited purposes set forth therein, Royalty Pharma PLC (the “Royalty Purchase Agreement”) (see Note 2), private placements of its convertible preferred stock, collaborations, bank and institutional lender debt, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company’s product candidates. Since 2014, the Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and since May 2017, the Company has generated revenue from net sales of Emflaza for the treatment of DMD in the United States. The Company has also relied on revenue associated with milestone and royalty payments from Roche pursuant to the License and Collaboration Agreement (the “SMA License Agreement”) dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation, under its SMA program. The Company expects that cash flows from the sales of its products, together with the Company’s cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months. </p>
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1702700000
CY2021Q1	ptct	Increase Decrease In Inventory For Clinical Development Programs And Marketing Efforts IncreaseDecreaseInInventoryForClinicalDevelopmentProgramsAndMarketingEfforts	0
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Company’s research and development expenses, valuation procedures for liability for sale of future royalties, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2021Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	7500000
CY2021Q1	ptct	Termforletterofcredit Termforletterofcredit	P5Y
CY2021Q1	ptct	Termforletterofcredit Termforletterofcredit	P5Y
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	146632000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	208812000
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	7500000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	7500000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154132000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	216312000
CY2020Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2021Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	678000
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	824000
CY2021Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	8401000
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	8745000
CY2021Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7155000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9128000
CY2021Q1	us-gaap	Inventory Net InventoryNet	16234000
CY2020Q4	us-gaap	Inventory Net InventoryNet	18697000
CY2021Q1	us-gaap	Inventory Write Down InventoryWriteDown	1400000
CY2020Q1	us-gaap	Inventory Write Down InventoryWriteDown	200000
CY2020Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	200000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000
CY2020Q3	ptct	Assigned Royalty Payment Retained Percentage AssignedRoyaltyPaymentRetainedPercentage	0.57067
CY2020Q3	ptct	Revenue Recognition Milestone Potential Achievements RevenueRecognitionMilestonePotentialAchievements	335000000.0
CY2021Q1	ptct	Deferred Payroll Tax Liability Cares Act DeferredPayrollTaxLiabilityCaresAct	2500000
CY2017Q4	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	122000000.0
CY2021Q1	ptct	Number Of Operating Leases NumberOfOperatingLeases	3
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	5400000
CY2020Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	2400000
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	4104000
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	2118000
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	1093000
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	228000
CY2021Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	164000
CY2020Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	77000
CY2021Q1	ptct	Lease Cost Excluding Finance Lease Costs LeaseCostExcludingFinanceLeaseCosts	5361000
CY2020Q1	ptct	Lease Cost Excluding Finance Lease Costs LeaseCostExcludingFinanceLeaseCosts	2423000
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	82382000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	84410000
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7333000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7465000
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	77863000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	79499000
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	85196000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	86964000
CY2021Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1694000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1276000
CY2021Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20053000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	23053000
CY2021Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	21747000
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	24329000
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y4M2D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y5M26D
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0888
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0886
CY2021Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P11Y9M
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P12Y
CY2021Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0780
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0780
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	3406000
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1971000
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2224000
CY2021Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	776000
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	13000
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	22642000
CY2021Q1	ptct	Fair Value Assets Transfers Between Level1 Level2 And Level3 Amount FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount	0
CY2020Q4	ptct	Fair Value Assets Transfers Between Level1 Level2 And Level3 Amount FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount	0
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	10242000
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	13240000
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	3000000
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	12843000
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	3000000
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	12150000
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	3000000
CY2021Q1	ptct	Lessee Operating Lease Liability To Be Paid Year Four And After LesseeOperatingLeaseLiabilityToBePaidYearFourAndAfter	91994000
CY2021Q1	ptct	Finance Lease Liability To Be Paid Year Four And After FinanceLeaseLiabilityToBePaidYearFourAndAfter	24000000
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	140469000
CY2021Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	33000000
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	55273000
CY2021Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	11253000
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	85196000
CY2021Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	21747000
CY2021Q1	ptct	Clearpoint Equity Investment Fvni Unrealized Gain Loss ClearpointEquityInvestmentFvniUnrealizedGainLoss	6800000
CY2020Q1	ptct	Clearpoint Equity Investment Fvni Unrealized Gain Loss ClearpointEquityInvestmentFvniUnrealizedGainLoss	-1600000
CY2021Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	27400000
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	20500000
CY2020Q1	ptct	Payments To Acquire Convertible Debt Investment PaymentsToAcquireConvertibleDebtInvestment	10000000.0
CY2020Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	6.00
CY2020Q1	ptct	Debt Instrument Convertible Period DebtInstrumentConvertiblePeriod	P5Y
CY2021Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	7900000
CY2020Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	2800000
CY2021Q1	ptct	Convertible Debt Security ConvertibleDebtSecurity	37100000
CY2020Q4	ptct	Convertible Debt Security ConvertibleDebtSecurity	29300000
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	200000000.0
CY2021Q1	ptct	Number Of Mutual Funds Invested In NumberOfMutualFundsInvestedIn	2
CY2021Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-300000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	75000
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	641471000
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	750000
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	144000
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	642077000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	892938000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1975000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	894838000
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0
CY2020Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0
CY2021Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	700000
CY2020Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0
CY2021Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	144000
CY2021Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	266050000
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	144000
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	266050000
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	75000
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	260970000
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	75000
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	260970000
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	450923000
CY2021Q1	ptct	Available For Sale Securities Debt Maturities Over One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue	191154000
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	588863000
CY2020Q4	ptct	Available For Sale Securities Debt Maturities Over One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue	305975000
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	24859000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	53291000
CY2021Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3909000
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4315000
CY2021Q1	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	23927000
CY2020Q4	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	18250000
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4685000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3614000
CY2021Q1	ptct	Sales Allowance And Other Related Costs SalesAllowanceAndOtherRelatedCosts	55638000
CY2020Q4	ptct	Sales Allowance And Other Related Costs SalesAllowanceAndOtherRelatedCosts	54327000
CY2021Q1	ptct	Sales Rebates Current SalesRebatesCurrent	49665000
CY2020Q4	ptct	Sales Rebates Current SalesRebatesCurrent	63774000
CY2021Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	16181000
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	16575000
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	19114000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18665000
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7658000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9357000
CY2021Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	205636000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	242168000
CY2020Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	262205
CY2020Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	13500000
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	0
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-128642000
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-112687000
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	70188602
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62389158
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.83
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.81
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12483840
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13597219
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25707000
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15220000
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	276700000
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y7D
CY2020Q3	ptct	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	650000000.0
CY2020Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.110
CY2020Q4	ptct	Liability Sale Of Future Royalties LiabilitySaleOfFutureRoyalties	679762000
CY2021Q1	ptct	Liability Sale Of Future Royalties Royalty Revenue Payable LiabilitySaleOfFutureRoyaltiesRoyaltyRevenuePayable	2858000
CY2021Q1	ptct	Liability Sale Of Future Royalties Interest Expense LiabilitySaleOfFutureRoyaltiesInterestExpense	18080000
CY2021Q1	ptct	Liability Sale Of Future Royalties LiabilitySaleOfFutureRoyalties	694984000
CY2021Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.106
CY2021Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021Q1	ptct	Numberofdistributors Numberofdistributors	2
CY2020Q1	ptct	Numberofdistributors Numberofdistributors	3
CY2021Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1900000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4200000
CY2021Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2100000
CY2020Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2000000.0
CY2021Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1900000
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	4200000
CY2021Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11300000
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7900000
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	33826000
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	45100000
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	45100000
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	7489000
CY2021Q1	ptct	Finite Lived Intangible Assets Amortization Expense Year Four And Thereafter FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndThereafter	4559000
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	136074000
CY2021Q1	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	576500000
	us-gaap	Indefinite Lived Intangible Assets Period Increase Decrease IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease	0
CY2021Q1	us-gaap	Goodwill Goodwill	82300000
CY2021Q1	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0

Files In Submission

Name	View Source	Status
0001070081-21-000017-index-headers.html	Edgar Link	pending
0001070081-21-000017-index.html	Edgar Link	pending
0001070081-21-000017.txt	Edgar Link	pending
0001070081-21-000017-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ptct-20210331.xsd	Edgar Link	pending
ptct-20210331ex101cf1a77.htm	Edgar Link	pending
ptct-20210331ex31128499b.htm	Edgar Link	pending
ptct-20210331ex312c36715.htm	Edgar Link	pending
ptct-20210331ex321c97942.htm	Edgar Link	pending
ptct-20210331ex3228cfd43.htm	Edgar Link	pending
ptct-20210331x10q.htm	Edgar Link	pending
ptct-20210331x10q_htm.xml	Edgar Link	completed
ptct-20210331_cal.xml	Edgar Link	unprocessable
ptct-20210331_def.xml	Edgar Link	unprocessable
ptct-20210331_lab.xml	Edgar Link	unprocessable
ptct-20210331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTCT
PTC THERAPEUTICS, INC. Stock $ptct

2021 Q1 Form 10-Q Financial Statement

#000107008121000017 Filed on May 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT PTC THERAPEUTICS, INC. Stock $ptct

2021 Q1 Form 10-Q Financial Statement

#000107008121000017 Filed on May 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT
PTC THERAPEUTICS, INC. Stock $ptct